Daraxonrasib: the pancreatic cancer drug that doubled survival

In late May 2026, results from the largest clinical trial ever conducted for a targeted pancreatic cancer therapy were presented at the American Society of Clinical Oncology Annual Meeting in Chicago and published simultaneously in the New England Journal of Medicine . The drug, daraxonrasib, nearly doubled median overall survival in patients with metastatic pancreatic cancer compared to standard chemotherapy. For a disease where more than half of patients die within three months of diagnosis, this is the most significant treatment advance in decades.

What makes this moment significant goes beyond one drug. It reveals that the biology of pancreatic cancer, long considered one of the most resistant cancers to targeted treatment, is starting to yield to precision medicine. And that the biggest variable in pancreatic cancer outcomes remains the same as it has always been: how early the cancer is found.

In Switzerland, around 1,500 people are diagnosed with pancreatic cancer each year . Roughly 12% survive five years. These numbers reflect late detection far more than they reflect untreatable biology. For context on the detection side of this equation, see our earlier article: Pancreatic cancer: the case for catching it early .

Why pancreatic cancer has been so hard to treat

Pancreatic cancer has resisted treatment strategies that work in other cancers. To understand why daraxonrasib matters, you need to understand what it's up against.

More than 90% of pancreatic ductal adenocarcinomas (the most common type, accounting for about 90% of cases) are driven by mutations in a gene called KRAS. KRAS produces a protein that acts as a molecular switch for cell growth. When mutated, the switch gets stuck in the "on" position, telling the cell to keep dividing (i.e. growing).

Scientists have known about KRAS since the 1980s. For nearly four decades, it was considered "undruggable." The protein's surface is smooth and compact, with no obvious pocket where a drug molecule could bind and block its activity. Other oncogenes had clear vulnerabilities. KRAS did not.

This meant that for decades, the only systemic treatment for advanced pancreatic cancer was chemotherapy, which targets all rapidly dividing cells rather than the specific mutation driving the cancer. Chemotherapy extends life modestly in metastatic disease: median overall survival with second-line chemotherapy is typically 6 to 7 months, with significant side effects.

What daraxonrasib actually does

Daraxonrasib belongs to a new class of drugs called RAS(ON) multi-selective inhibitors. The name describes the mechanism: the drug targets the RAS protein while it is in its active ("on") state, which is where it does its damage.

Previous attempts at RAS inhibitors could only target one specific mutation variant at a time (for example, KRAS G12C, which is common in lung cancer but rare in pancreatic cancer). The most common KRAS mutations in pancreatic cancer, G12D and G12V, remained out of reach.

Daraxonrasib works differently. It acts as a molecular glue: it binds first to a naturally occurring protein in the body called cyclophilin A, and this two-molecule complex then latches onto the active RAS protein, blocking it from signaling downstream growth pathways. Because this mechanism targets the RAS protein broadly, rather than one specific mutation, daraxonrasib is effective across multiple KRAS variants and even in tumors without an identified RAS mutation.

The RASolute 302 trial: what the data shows

The RASolute 302 trial was a global, randomized Phase 3 study that enrolled 500 patients with metastatic pancreatic cancer who had already received one line of chemotherapy. Patients were randomly assigned to receive either daraxonrasib or a second round of chemotherapy chosen by their oncologist.

The results, presented by Brian Wolpin, MD of the Dana-Farber Cancer Institute:

• Overall survival. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The hazard ratio was 0.40, meaning daraxonrasib reduced the risk of death by 60% compared to chemotherapy (p < 0.0001).
• Progression-free survival. Median progression-free survival was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.
• Tumor response. 31.6% of patients on daraxonrasib experienced substantial tumor shrinkage or disappearance, compared to 11.2% on chemotherapy.
• Side effects. Daraxonrasib caused fewer serious adverse events. Grade 3 or higher adverse events occurred in 43.6% of the daraxonrasib group versus 57.5% of the chemotherapy group. Only 1.2% of patients on daraxonrasib stopped treatment due to side effects, compared to 11.2% on chemotherapy. The most common side effects were rash, mouth inflammation, nausea, and diarrhea.

These numbers are unprecedented for second-line pancreatic cancer treatment.

What changes now

The FDA granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic pancreatic cancer. Revolution Medicines , the company that developed the drug, intends to submit the data for regulatory approval. On May 1, 2026, the FDA granted permission for an expanded access program, making daraxonrasib available to eligible patients before formal approval.

A separate trial, RASolute 303, is already evaluating daraxonrasib as a first-line treatment, meaning it could potentially be used before chemotherapy rather than after it. If those results are positive, the treatment sequence for pancreatic cancer could shift fundamentally.

Daraxonrasib is also being tested in other RAS-driven cancers, including non-small cell lung cancer and colorectal cancer.

But a note of realism: daraxonrasib is not a cure. A median overall survival of 13.2 months in metastatic disease is a dramatic improvement over 6.7 months, and it meaningfully extends life while reducing treatment burden. It does not, however, change the fundamental challenge of late-stage diagnosis. The five-year survival rate for metastatic pancreatic cancer remains very low.

Why detection still matters most

Every advance in pancreatic cancer treatment underscores the same point: the earlier the cancer is found, the more any treatment can offer.

When pancreatic cancer is caught at Stage I, still confined to the organ, surgery is possible and five-year survival rates improve substantially. When it is found after metastasis, even a breakthrough drug like daraxonrasib is extending life by months, not by decades.

About 80% of pancreatic cancer patients are diagnosed at an advanced or metastatic stage. There is no population-wide screening program for pancreatic cancer in Switzerland or anywhere else. Symptoms are vague and easily mistaken for common digestive issues: upper abdominal pain, unexplained weight loss, new-onset diabetes, fatigue. By the time a diagnosis arrives, curative surgery is usually no longer an option.

This is the asymmetry that makes early detection so valuable. A drug that doubles survival in late-stage disease is important. A scan that catches the cancer before it leaves the pancreas changes the category of outcomes entirely.

At Ahead Health, full-body MRI can detect pancreatic abnormalities, including cysts and small lesions, before they cause symptoms. This is particularly relevant for people with elevated risk factors: family history of pancreatic cancer, BRCA1 or BRCA2 mutations, chronic pancreatitis, long-standing type 2 diabetes, or a smoking history.

How Ahead Health supports early detection

Ahead's full-body MRI delivers radiation-free imaging of the entire body, including the pancreas and surrounding abdominal organs. It can reveal pancreatic cysts, structural abnormalities, and masses too small to cause symptoms but significant enough to warrant monitoring or further investigation.

The Ahead Core package (CHF 1,990) includes the full-body MRI and a health report reviewed by Swiss board-certified physicians. For a more complete picture, the Ahead Advanced package (CHF 2,490) adds an 80+ biomarker blood panel covering metabolic markers relevant to pancreatic health, including blood glucose, HbA1c, insulin, and liver enzymes that can signal early pancreatic dysfunction.

The Ahead Pro package (CHF 3,549) includes everything in Advanced plus additional imaging analyses and hormone panels.

Every scan is supported by AI-assisted analysis, helping the medical team identify subtle patterns with greater precision.

Supplementary health insurers may cover part of the cost for our full-body check-ups. For example, KPT's supplementary insurance 'Pulse' reimburses up to CHF 1,500 for Ahead Health services.

Conclusion

Daraxonrasib is the first targeted therapy to demonstrate a clear survival benefit in pancreatic cancer, and its mechanism opens a door that was closed for nearly four decades. The treatment landscape for this disease is changing. But a breakthrough in late-stage treatment does not reduce the importance of early detection. If anything, it raises the stakes: the more effective treatments become, the greater the value of finding the cancer early enough for those treatments to work alongside surgery, not instead of it.